Immix Biopharma Secures Strategic Investment from Goose Capital for AL Amyloidosis CAR-T Therapy
核心洞察
Immix Biopharma received strategic investment from Goose Capital (搜索), led by former Tanox (搜索) CEO Dr. Nancy T. Chang, who previously developed FDA-approved drugs generating over $5 billion in sales.
The investment supports commercialization of NXC-201, a BCMA (搜索)-targeted CAR-T therapy for relapsed/refractory AL Amyloidosis (搜索) that met its primary endpoint in the NEXICART-2 trial.
NXC-201 has received FDA Regenerative Medicine Advanced Therapy designation and Orphan Drug Designation from both FDA and EMA.
Immix Biopharma announced it has secured a strategic investment from Houston-based Goose Capital (搜索), led by founding member Dr. Nancy T. Chang, former CEO of Tanox (搜索), Inc. The investment aims to advance the commercialization of NXC-201, the company's lead CAR-T cell therapy for AL Amyloidosis (搜索).
Dr. Chang brings significant pharmaceutical development expertise to the partnership. At Tanox (搜索), she and her team invented and developed three FDA-approved drugs: XOLAIR® (omalizumab) for severe asthma (搜索), TROGARZO® (ibalizumab-uiyk) for HIV (搜索), and EBGLYSS® (lebrikizumab-lbkz) for dermatitis (搜索). These drugs have collectively generated sales exceeding $5 billion. Tanox was subsequently acquired by Genentech/Roche, while EBGLYSS® is now commercialized by Eli Lilly and Co.
Strategic Partnership Details
"Immix's mission of curing the incurable resonates with Goose's goal of investing in breakthrough technologies and innovative founders to forge the future of human medicine," said Anthony George, President of Goose Capital (搜索). Ashok Rao, Board Member of Goose Capital, added, "After a deep evaluation of the technology, team, and market that Immix is pursuing, we are pleased to support, and anticipate exciting progress to-come."
Ilya Rachman, M.D., Ph.D., Chief Executive Officer of Immix Biopharma, expressed enthusiasm about the partnership: "We are thrilled that Dr. Chang and Goose recognize the opportunity for commercialization of NXC-201 in relapsed/refractory AL Amyloidosis (搜索), other serious diseases, and beyond."
NXC-201 Clinical Development
NXC-201 is a sterically-optimized BCMA (搜索)-targeted chimeric antigen receptor T (CAR-T) cell therapy featuring a "digital filter" that filters out non-specific activation. The therapy is currently being evaluated in NEXICART-2 (NCT06097832), a U.S. multi-center Phase 1/2 study for relapsed/refractory AL Amyloidosis (搜索) with a registrational design.
The trial has shown promising results, with the primary endpoint met at interim results presented at ASCO 2025. This clinical success has contributed to NXC-201 receiving significant regulatory recognition, including Regenerative Medicine Advanced Therapy (RMAT) designation from the US FDA and Orphan Drug Designation (ODD) from both the FDA and the European Medicines Agency (EMA).
Investment Impact
Gabriel Morris, Chief Financial Officer of Immix Biopharma, highlighted the strategic value of the partnership: "Goose and Dr. Chang bring unparalleled experience to the Immix team. Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, further enabling our goal to deliver widely accessible cures, as patients are waiting."
The investment from Goose Capital (搜索), an investment firm comprised of former Fortune 500 executives, industry leaders, and serial entrepreneurs, provides both financial support and strategic expertise for Immix's continued development of cell therapies for AL Amyloidosis (搜索) and other serious diseases.